Crinetics Pharmaceuticals
CRNX
CRNX was delisted on the 31st of August, 2026.
234 hedge funds and large institutions have $3.69B invested in Crinetics Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 48 funds opening new positions, 103 increasing their positions, 57 reducing their positions, and 16 closing their positions.
200% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 16
81% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 57
53% more call options, than puts
Call options by funds: $13.5M | Put options by funds: $8.82M
15% more funds holding
Funds holding: 203 → 234 (+31)
1.4% more ownership
Funds ownership: 103.2% → 104.6% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 13 → 13 (0)
2% less capital invested
Capital invested by funds: $3.76B → $3.69B (-$68.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$76.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$43.4M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$40.9M |
| 4 |
BlackRock
New York
|
+$36.7M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$26.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$100M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$60.4M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
-$28.2M |
| 4 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$22.6M |
| 5 |
State Street
Boston,
Massachusetts
|
-$20.4M |
CRNX Hedge Fund Activity: Q2 2024 in Review
234 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q2 2024, worth a combined $3.69B — down 1.8% from $3.76B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new CRNX positions and 16 closed out — a net gain of 32 holders — while 103 added to existing stakes and 57 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $76.1M. The largest seller was Point72 Asset Management, cutting an estimated $100M.
- 234 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q2 2024, up from 203 in Q1 2024.
- Funds reported $3.69B of Crinetics Pharmaceuticals stock for Q2 2024, down 1.8% quarter-over-quarter.
- 48 funds opened new Crinetics Pharmaceuticals positions in Q2 2024 and 16 closed out, a net change of +32 holders.
- The largest Crinetics Pharmaceuticals buyer in Q2 2024 was Wellington Management Group, an estimated $76.1M added.
- The largest Crinetics Pharmaceuticals seller in Q2 2024 was Point72 Asset Management, an estimated $100M sold.
Based on aggregated 13F filings for Q2 2024.